X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2022/12/16/2575746/0/en/The-CHMP-has-Adopted-a-Negative-Opinion-for-Omburtamab-for-the-Treatment-of-CNS-LM-Metastasis-from-Neuroblastoma-in-Europe.html
https://health.economictimes.indiatimes.com/news/pharma/u-s-fda-declines-to-approve-y-mabss-pediatric-cancer-drug/95930439
https://www.globenewswire.com//news-release/2022/12/01/2566388/0/en/Y-mAbs-Announces-Complete-Response-Letter-for-Omburtamab-Biologics-License-Application.html
https://www.fiercebiotech.com/biotech/y-mabs-rare-disease-drug-roundly-rejected-fda-adcomm-over-weakness-single-arm-trial
https://www.globenewswire.com/news-release/2022/10/28/2544126/0/en/Y-mAbs-Announces-Outcome-of-FDA-Advisory-Committee-Meeting-on-Omburtamab.html
https://www.globenewswire.com/news-release/2022/10/03/2526934/0/en/Y-mAbs-Announces-Pivotal-Data-for-Omburtamab.html
https://www.globenewswire.com/news-release/2022/05/31/2453349/0/en/Y-mAbs-Announces-FDA-Acceptance-of-Biologics-License-Application-for-OMBLASTYS-omburtamab-for-the-Treatment-of-Neuroblastoma-for-Priority-Review.html
https://www.globenewswire.com/news-release/2022/04/01/2414852/0/en/Y-mAbs-Announces-Submission-of-Omburtamab-Biologics-License-Application-to-FDA.html
https://www.globenewswire.com/news-release/2021/11/04/2327599/0/en/Y-mAbs-Provides-Regulatory-Update-on-Omburtamab-for-the-Treatment-of-Patients-with-Neuroblastoma-CNS-LM-Metastasis.html
https://www.streetinsider.com/Corporate+News/Y-mAbs+Therapeutics+%28YMAB%29%2C+Takeda+%28TAK%29+Announce+Exclusive+License+and+Distribution+Agreement+for+DANYELZA%C2%AE+%28naxitamab-gqgk%29+and+Omburtamab+in+Israel/17683384.html
https://www.biospace.com/article/releases/y-mabs-announces-fda-clearance-of-ind-for-lutetium-177-labeled-omburtamab-antibody-for-adult-indications/
https://endpts.com/fda-hands-y-mabs-refusal-to-file-letter-in-one-of-its-pediatric-neuroblastoma-programs/
https://www.globenewswire.com/news-release/2020/06/30/2055790/0/en/Y-mAbs-Announces-Initiation-of-Submission-of-Omburtamab-Rolling-Biologics-License-Application-to-the-FDA.html
https://www.globenewswire.com/news-release/2020/02/26/1991340/0/en/Y-mAbs-Announces-Positive-Pre-BLA-Meeting-with-FDA-for-Omburtamab.html
https://www.contractpharma.com/contents/view_breaking-news/2019-07-03/y-mabs-secures-commercial-radiolabeling-capacity/
Market Place
Share 
